Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) shares rose 8.4% during trading on Wednesday . The company traded as high as $17.39 and last traded at $17.40. Approximately 371,403 shares traded hands during trading, a decline of 68% from the average daily volume of 1,151,021 shares. The stock had previously closed at $16.05.
Wall Street Analyst Weigh In
VRDN has been the topic of a number of recent research reports. Needham & Company LLC restated a "buy" rating and set a $36.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, May 20th. Royal Bank Of Canada reduced their price objective on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright restated a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. The Goldman Sachs Group reduced their price objective on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, JMP Securities reduced their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $37.56.
Read Our Latest Research Report on VRDN
Viridian Therapeutics Stock Performance
The firm has a market capitalization of $1.40 billion, a PE ratio of -4.44 and a beta of 0.39. The company has a debt-to-equity ratio of 0.05, a current ratio of 19.49 and a quick ratio of 19.49. The stock has a 50-day moving average price of $14.24 and a 200-day moving average price of $15.50.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.61% and a negative net margin of 102,092.39%. The firm had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.16 million. Viridian Therapeutics's quarterly revenue was up .0% on a year-over-year basis. On average, research analysts expect that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.
Hedge Funds Weigh In On Viridian Therapeutics
Several institutional investors have recently made changes to their positions in VRDN. Nuveen Asset Management LLC boosted its position in shares of Viridian Therapeutics by 198.2% during the fourth quarter. Nuveen Asset Management LLC now owns 681,012 shares of the company's stock worth $13,055,000 after buying an additional 452,627 shares during the period. Vanguard Group Inc. boosted its position in shares of Viridian Therapeutics by 4.0% during the fourth quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company's stock worth $88,087,000 after buying an additional 174,952 shares during the period. Rhumbline Advisers boosted its position in shares of Viridian Therapeutics by 4.6% during the first quarter. Rhumbline Advisers now owns 104,559 shares of the company's stock worth $1,409,000 after buying an additional 4,621 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Viridian Therapeutics by 11.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 575,070 shares of the company's stock worth $11,024,000 after buying an additional 58,857 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Viridian Therapeutics by 29.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 115,782 shares of the company's stock worth $2,220,000 after buying an additional 26,286 shares during the period.
Viridian Therapeutics Company Profile
(
Get Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Further Reading
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
